Your browser doesn't support javascript.
loading
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.
Fachal, Laura; Aschard, Hugues; Beesley, Jonathan; Barnes, Daniel R; Allen, Jamie; Kar, Siddhartha; Pooley, Karen A; Dennis, Joe; Michailidou, Kyriaki; Turman, Constance; Soucy, Penny; Lemaçon, Audrey; Lush, Michael; Tyrer, Jonathan P; Ghoussaini, Maya; Moradi Marjaneh, Mahdi; Jiang, Xia; Agata, Simona; Aittomäki, Kristiina; Alonso, M Rosario; Andrulis, Irene L; Anton-Culver, Hoda; Antonenkova, Natalia N; Arason, Adalgeir; Arndt, Volker; Aronson, Kristan J; Arun, Banu K; Auber, Bernd; Auer, Paul L; Azzollini, Jacopo; Balmaña, Judith; Barkardottir, Rosa B; Barrowdale, Daniel; Beeghly-Fadiel, Alicia; Benitez, Javier; Bermisheva, Marina; Bialkowska, Katarzyna; Blanco, Amie M; Blomqvist, Carl; Blot, William; Bogdanova, Natalia V; Bojesen, Stig E; Bolla, Manjeet K; Bonanni, Bernardo; Borg, Ake; Bosse, Kristin; Brauch, Hiltrud; Brenner, Hermann; Briceno, Ignacio; Brock, Ian W.
Afiliación
  • Fachal L; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Aschard H; Centre de Bioinformatique Biostatistique et Biologie Intégrative (C3BI), Institut Pasteur, Paris, France.
  • Beesley J; Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Barnes DR; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Allen J; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Kar S; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Pooley KA; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Dennis J; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Michailidou K; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Turman C; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Soucy P; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Lemaçon A; Department of Electron Microscopy/Molecular Pathology and The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
  • Lush M; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Tyrer JP; Genomics Center, Centre Hospitalier Universitaire de Québec, Université Laval Research Center, Québec City, Québec, Canada.
  • Ghoussaini M; Genomics Center, Centre Hospitalier Universitaire de Québec, Université Laval Research Center, Québec City, Québec, Canada.
  • Moradi Marjaneh M; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Jiang X; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Agata S; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Aittomäki K; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Alonso MR; UK Dementia Research Institute, Imperial College London, London, UK.
  • Andrulis IL; Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Anton-Culver H; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology (IOV), IRCCS, Padua, Italy.
  • Antonenkova NN; Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Arason A; Human Genotyping-CEGEN Unit, Human Cancer Genetic Program, Spanish National Cancer Research Centre, Madrid, Spain.
  • Arndt V; Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Aronson KJ; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Arun BK; Department of Epidemiology, Genetic Epidemiology Research Institute, University of California, Irvine, Irvine, CA, USA.
  • Auber B; N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus.
  • Auer PL; Department of Pathology, Landspitali University Hospital, Reykjavik, Iceland.
  • Azzollini J; BMC (Biomedical Centre), Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Balmaña J; Division of Clinical Epidemiology and Aging Research (C070), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Barkardottir RB; Department of Public Health Sciences and Cancer Research Institute, Queen's University, Kingston, Ontario, Canada.
  • Barrowdale D; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Beeghly-Fadiel A; Institute of Human Genetics, Hannover Medical School, Hannover, Germany.
  • Benitez J; Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Bermisheva M; Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
  • Bialkowska K; Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
  • Blanco AM; High Risk and Cancer Prevention Group, Vall Hebron Institute of Oncology, Barcelona, Spain.
  • Blomqvist C; Department of Medical Oncology, Vall Hebron University Hospital, Barcelona, Spain.
  • Blot W; Department of Pathology, Landspitali University Hospital, Reykjavik, Iceland.
  • Bogdanova NV; BMC (Biomedical Centre), Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Bojesen SE; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Bolla MK; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Bonanni B; Centro de Investigación en Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
  • Borg A; Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Bosse K; Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia.
  • Brauch H; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Brenner H; Cancer Genetics and Prevention Program, University of California, San Francisco, San Francisco, CA, USA.
  • Briceno I; Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Brock IW; Department of Oncology, Örebro University Hospital, Örebro, Sweden.
Nat Genet ; 52(1): 56-73, 2020 01.
Article en En | MEDLINE | ID: mdl-31911677
ABSTRACT
Genome-wide association studies have identified breast cancer risk variants in over 150 genomic regions, but the mechanisms underlying risk remain largely unknown. These regions were explored by combining association analysis with in silico genomic feature annotations. We defined 205 independent risk-associated signals with the set of credible causal variants in each one. In parallel, we used a Bayesian approach (PAINTOR) that combines genetic association, linkage disequilibrium and enriched genomic features to determine variants with high posterior probabilities of being causal. Potentially causal variants were significantly over-represented in active gene regulatory regions and transcription factor binding sites. We applied our INQUSIT pipeline for prioritizing genes as targets of those potentially causal variants, using gene expression (expression quantitative trait loci), chromatin interaction and functional annotations. Known cancer drivers, transcription factors and genes in the developmental, apoptosis, immune system and DNA integrity checkpoint gene ontology pathways were over-represented among the highest-confidence target genes.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias de la Mama / Biomarcadores de Tumor / Mapeo Cromosómico / Predisposición Genética a la Enfermedad / Polimorfismo de Nucleótido Simple / Sitios de Carácter Cuantitativo / Estudio de Asociación del Genoma Completo Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Nat Genet Asunto de la revista: GENETICA MEDICA Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias de la Mama / Biomarcadores de Tumor / Mapeo Cromosómico / Predisposición Genética a la Enfermedad / Polimorfismo de Nucleótido Simple / Sitios de Carácter Cuantitativo / Estudio de Asociación del Genoma Completo Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Nat Genet Asunto de la revista: GENETICA MEDICA Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido